Expression of p53 and TP53 mutational analysis in malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma, sporadic or associated with brooke-spiegler syndrome

American Journal of Dermatopathology

Volumn 32, Issue 3, 2010, Pages 215-221

  Kazakov, Dmitry V ^a   Grossmann, Petr ^a   Spagnolo, Dominic V ^b   Vanecek, Tomas ^a   Vazmitel, Marina ^c   Kacerovska, Denisa ^a   Zelger, Bernhard ^d   Calonje, Eduardo ^e   Michal, Michal ^a,f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c INSTITUTE FOR MATHEMATICS   (Belarus)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f BIOPTICAL LABORATORY   (Czech Republic)

Author keywords

Brooke Spiegler syndrome; Cylindroma; Malignant spiradenoma; P53; Spiradenocylindroma; TP53 gene

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; AUTOSOMAL DISORDER; BROOKE SYNDROME; CLINICAL ARTICLE; CYLINDROMA; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HIDRADENOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOID CYSTIC; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; POINT MUTATION; SWEAT GLAND NEOPLASMS; SYNDROME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77951716589     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181b9678c     Document Type: Article

References (12)

1. Kazakov DV, Zelger B, Rutten A, et al. Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. Am J Surg Pathol. 2009;33:705-719.
2. Biernat W, Wozniak L. p53 expression in sweat gland tumors. Pol J Pathol. 1996;47:3-6.
3. Carlsten JR, Lewis MD, Saddler K, et al. Spiradenocylindrocarcinoma: a malignant hybrid tumor. J Cutan Pathol. 2005;32:166-171.
4. Lee HH, Lee KG. Malignant eccrine spiradenoma with florid squamous differentiation. J Korean Med Sci. 1998;13:191-195.
5. Kazakov DV, Ivan D, Kutzner H, et al. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis and t(11;19) translocation. Am J Dermatopathol. 2009;31: 236-247.
6. McCluggage WG, Fon LJ, O'Rourke D, et al. Malignant eccrine spiradenoma with carcinomatous and sarcomatous elements. J Clin Pathol. 1997;50:871-873.
7. Wong KB, DeDecker BS, Freund SM, et al. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A. 1999;96:8438-8442.
8. Alsner J, Jensen V, Kyndi M, et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 2008;47:600-607. (Pubitemid 351878460)
9. Park YK, Park HR, Chi SG, et al. Overexpression of p53 and rare genetic mutation in mesenchymal chondrosarcoma. Oncol Rep. 2000;7:1041-1047.
10. Babjuk M, Soukup V, Mares J, et al. The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. Int Urol Nephrol. 2002;34:495-501.
11. Wang YC, Lin RK, Tan YH, et al. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol. 2005;23:154-164.
12. Chang-Claude J, Dunning A, Schnitzbauer U, et al. The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. Int J Cancer. 2003;103:779-783.